Skip to main content Skip to footer
Aurinia Pharmaceuticals Inc.
Aurinia Pharmaceuticals Inc.
  • Home
  • About Us
    • Our Story
    • Our Mission, Vision, Values
    • Our Team
    • Our Partners
    • Investors & Media
  • Patients
    • About Lupus Nephritis
    • Resources
    • Patient Support Program
    • Aurinia in Action
  • Our Science
    • Our Product
    • Our Pipeline
    • Our Research and Data
  • Investors & Media
    • News & Events
    • Corporate Presentation
    • Financial Info
    • Stock Data
    • SEC Filings
    • ESG
    • Board of Directors
    • Governance
    • Investor Tools
  • Aurinia Gives
    • Aurinia Gives
    • CME Grants
    • Charitable Giving FAQs
    • Sponsorships
    • Charitable Donations
    • Patient-Centered Care Grants
  • Careers
    • Our Culture
    • Our Benefits
    • Notice to Recruiters
    • Careers Contact
    • Open Positions
  • Contact Us
    • Report an Adverse Event

Press Releases

Investors & Media

Investors & Media

  • News & Events
    • Press Releases
    • IR Calendar
    • 2025 AGM
  • Corporate Presentation
    • Corporate Presentation
  • Financial Info
    • Financial Results
  • Stock Data
    • Charts
    • Historical Data
    • Analyst Coverage
  • SEC Filings
    • Overview
    • All SEC Filings
    • Annual Filings
  • ESG
  • Board of Directors
  • Governance
  • Investor Tools
    • Overview
    • Email Alerts
    • Contacts
    • RSS News Feed
  • News & Events

  • Press Releases
  • IR Calendar
  • 2025 AGM
May 2, 2024 • 6:00 am EDT

Aurinia Pharmaceuticals Reports First Quarter 2024 Financial and Operational Results

May 1, 2024 • 6:00 am EDT

Aurinia Underscores Enduring Commitment to People Living with Lupus Nephritis Through Innovative Advocacy and Education Initiatives for Lupus Awareness Month

April 30, 2024 • 6:00 am EDT

The U.S. Food & Drug Administration (FDA) Approves Updated LUPKYNIS® (voclosporin) Label to include Long-Term Data from the AURORA Clinical Program

April 16, 2024 • 10:48 am EDT

UPDATE: New Aurinia Presentation Details at the 2024 Bloom Burton & Co. Healthcare Investor Conference

April 15, 2024 • 6:00 am EDT

Aurinia Pharmaceuticals to Release First Quarter Financial and Operational Results on May 2, 2024

February 29, 2024 • 8:30 am EST

Aurinia Receives Exemptive Relief from Canadian Securities Regulators for Share Repurchase Program

February 27, 2024 • 8:30 am EST

Aurinia to Participate in Upcoming Investor Healthcare Conferences

February 15, 2024 • 6:00 am EST

Aurinia Discloses 2023 Year-End Financial and Operational Results, Announces Corporate Actions Focused on Enhancing Shareholder Value

February 5, 2024 • 8:30 am EST

Aurinia Pharmaceuticals to Release 2023 Fourth Quarter and Full Year Financial and Operational Results on February 15, 2024

January 5, 2024 • 6:00 am EST

Aurinia Provides Preliminary Unaudited Fourth Quarter and Full-Year 2023 Net Revenue Results

  • Previous Pagearrow_back
  • Page 1
  • Page 2
  • Page 3
  • Page 4
  • Page 5
  • Page 6
  • Page 7
  • Page 8
  • Page 9
  • Page 10
  • …
  • Page 35
  • Next Pagearrow_forward
rss_feed News RSS
  • Email Alerts
  • Company Profile
  • Contacts
  • RSS News Feed

<h2>We are passionate about changing the trajectory of autoimmune diseases.<br>Join us.</h2>

Business Development

bd@auriniapharma.com

Investor Relations

ir@auriniapharma.com

Clinical Trials

clinicaltrials@auriniapharma.com

Medical Information

medinfo@auriniapharma.com

Corporate Communications and Media Inquiries

AChristopher@auriniapharma.com

Patient Safety

Report an Adverse Event
Privacy Statement Terms of Use Disclaimer Aurinia Community Guidelines Aurinia Compliance Program Manage Cookie Preferences
©2025 Aurinia Pharmaceuticals Inc. All Rights Reserved. US-LUP-2300105 08/23
Back to top

Navigating away from Aurinia

You are about to leave the Aurinia Pharmaceuticals website. We are not responsible for the content or accuracy of information on any third-party websites nor do we monitor or endorse such websites. If you would like to leave the Aurinia website and visit the third-party website, please select CONTINUE.